Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in an all-cash transaction, representing a 102% premium to Crinetics' closing price on Monday and valuing the company's equity at approximately $10 billion, or $8.8 billion net of estimated cash acquired. The deal was unanimously approved by both companies' boards and is expected to close in the third quarter of 2026, subject to Crinetics shareholder approval and standard regulatory clearances.
The acquisition adds two late-stage and commercial endocrinology assets to Vertex's pipeline. PALSONIFY, known generically as paltusotine, received FDA approval in September 2025 and European Medicines Agency approval shortly thereafter, making it the first and only once-daily oral therapy for adults with acromegaly, a rare hormonal disorder caused by excess growth hormone. Vertex also gains atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia, a rare adrenal disorder affecting cortisol production. Management said the two assets together carry a combined peak annual revenue potential of more than $5 billion, with the transaction expected to become accretive to non-GAAP operating income in 2029.
Vertex will finance the deal using a combination of cash on hand and debt, backed by $4.5 billion in fully committed bridge financing from Bank of America and Morgan Stanley Senior Funding. The company had previously flagged intentions to diversify beyond cystic fibrosis, its current dominant franchise, and analysts said the Crinetics deal fits that strategy by adding a commercial-stage rare-disease product with an already-approved regulatory pathway in multiple geographies.
Shares of Crinetics nearly doubled in after-hours trading following the announcement, consistent with the scale of the premium. Vertex shares fell roughly 2% in the extended session, a modest reaction that analysts attributed to the deal's size relative to Vertex's cash position and the timeline to earnings accretion. The company's 2026 guidance will be updated upon closing, with management noting the transaction will have only a modest impact on current-year revenue and non-GAAP operating expenses given the anticipated Q3 closing date.
The deal carries broader implications for the specialty endocrinology sector and for biotech M&A activity more generally. Acromegaly and congenital adrenal hyperplasia are both areas with high unmet need and a limited number of approved therapies, making them attractive targets for acquirers seeking orphan drug economics — including pricing power, regulatory exclusivity, and relatively straightforward commercial launch pathways in defined patient populations. The Crinetics acquisition follows a pattern of large biotechs adding smaller, late-stage companies with single approved assets and adjacent pipeline candidates, a strategy that reduces binary clinical risk while providing immediate commercial-stage revenue.
Crinetics had been developing its endocrine pipeline for several years and launched PALSONIFY's US commercial rollout in October 2025. The acromegaly market is estimated at roughly $2 billion globally, with PALSONIFY competing primarily against injectable somatostatin analogs, where oral administration represents a meaningful clinical differentiation. Atumelnant's Phase 3 program in congenital adrenal hyperplasia, if successful, would address an indication with no currently approved oral treatment and significant quality-of-life burden for patients.